Browsing: Homepage Slider
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
Find out about IMPACT, a partnership between Anthony Nolan, Leuka, NHS Blood and Transplant and the University of Birmingham (UK), which aims to deliver the UK’s first large-scale clinical trials program in this exclusive blog piece.
In this interview with the Vice President of Global Development at Amgen we take a more in-depth look at the trastuzumab data, an oncology biosimilar medicine.
In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2017.
PROGRAM OVERVIEW This case-based enduring activity will cover the treatment and management of patients with advanced solid tumors who are…